Department of Health and Human Services
Public Health Service
Office of Compliance
October 12, 2006
VIA CERTIFIED MAIL, RETURN RECEIPT REQUESTED
PO Box 5600
Eureka, CA 95502
Dear Ms Smith:
This is to advise you that the Food and Drug Administration (FDA) has reviewed your website at the Internet address www.natrhealth.com and has determined that the product FoodMatrix diabetic pack (U1traGard Forte, Omegatone, Calcitone, and Carbotone) is promoted for conditions that cause these products to be drugs under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 USC 321(g)(1)]. The therapeutic claims on your website establish that this product is a drug because it is intended for use in the cure, mitigation, treatment, or prevention of disease. The marketing of this product with these claims violates the Act.
Examples of some of the claims observed on your website include:
- FoodMatrix Pack
- "In 1999 a clinical study was conducted at the Southeastern Institute for Biomedical Research to confirm corosolic acid's effect in lowering blood glucose levels in type 2 diabetics. After just 30 days, these were the results: [a]n average of 31.9% lower blood sugar levels … (l)owered blood cholesterol levels … [t]he FoodMatrix Diabetic Pack is also getting results with type 1 diabetics. It helps increase the sensitivity of the cells to insulin, which increases the effectiveness of the insulin a type 1 diabetic must take. This enables them to reduce both the insulin dosage and frequency of use."
- "Lower your blood sugar levels naturally without having to use drugs or insulin."
- "(UltraGard Forte): "Scientifically documented benefits that have been observed include: [r]educed adverse allergic and inflammatory diseases"
Furthermore, your product is not generally recognized as safe and effective for the above referenced conditions, and, therefore, the product is also a "new drug" under section 201(p) of the Act [21 USC 321(p)]. New drugs may not be legally marketed in the US without prior approval from FDA as described in section 505(a) of the Act [21 USC 355(a)]. FDA approves a new drug on the basis of scientific data submitted by a drug sponsor to demonstrate that the drug is safe and effective.
This product is also misbranded within the meaning of Section 502(f)(1) of the Act, in that the labeling for this drug fails to bear adequate directions for use [21 USC 352(t)(1)]
The above violations are not meant to be an all-inclusive list of deficiencies in your products and their labeling. While reviewing your website, we noticed that you promoted other products for disease treatment and/or prevention. It is your responsibility to ensure that products marketed by your firm comply with the Act and its implementing regulations. We urge you to review your website, product labels, and other labeling and promotional materials for your products to ensure that the claims you make for your products do not cause them to violate the Act.
Failure to promptly correct the violations specified above may result in enforcement action without further notice. Enforcement action may include seizure of violative products and/or injunction against the manufacturers and distributors of violative products.
Please advise this office in writing, within 15 working days of receipt of this letter, as to the specific steps you have taken or will be taking to correct these violations, including the steps taken to assure that similar violations do not recur. Include any documentation necessary to show that correction has been achieved. If you cannot complete all corrections before you respond, we expect that you will explain the reason for your delay and state when you will correct any remaining deviations.
Your reply should be sent to the attention of Quyen Tien, Compliance Officer, US Food and Drug Administration, Center for Food Safety and Applied Nutrition, Office of Compliance (HFS-607), 5100 Paint Branch Pkwy, College Park, MD 20740.
Joseph R. Baca
This page was posted on February 12, 2008.